pm 185184

Secnidazole (PM-185184) is a second-generation 5-nitroimidazole antimicrobial that is structurally related to other 5-nitroimidazoles including [DB00916] and [DB00911], but displays improved oral absorption and longer terminal elimination half-life than antimicrobial agents in this class [A27210]. Secnidazole is selective against many anaerobic Gram-positive and Gram-negative bacteria and protozoa.

Secnidazole hemihydrate (RP-14539), an orally ingestible azole derivative antibiotic and imidazole-based Serratia marcescens virulence suppressor, analogously inhibits acylhomoserine lactones, mitigating Pseudomonas aeruginosa pathogenicity through quorum sensing (QS) disruption. This compound exhibits broad-spectrum antimicrobial efficacy against numerous anaerobic Gram-negative and Gram-positive bacteria in vitro. Its therapeutic application spans the study and treatment of ailments including amoebiasis, giardiasis, and bacterial vaginitis [1] [2] [3].